Singapore, March 25 -- South Korea-based LigaChem Biosciences has announced a $25 million strategic investment in its partner, Iksuda Therapeutics, with the purpose of participating in its management.

This funding will accelerate the clinical development of Iksuda's Antibody-Drug Conjugate (ADC) pipeline, bringing forward the timeline for global commercialisation.

In particular, Iksuda plans to expand its global clinical trials for its Caxmotabart Entudotin (HER2-ADC) by focusing on patients who have developed resistance to currently marketed competing ADC drugs, thereby accelerating its sub-license to third parties and increasing its overall value.

Alongside the equity investment, LigaChem Bio has secured rights to purchase shares fro...